Cencora, Inc.

COR · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$415K – −$101K 5 disclosures · 1 bought / 4 sold · last Jun 12, 2026
Jared Moskowitz D · HOUSE · FL	−$13K – $29K −$18K – $30K today 3 filings · last May 6, 2026
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $16K today 1 filing · last Mar 27, 2026
Thomas R. Carper D · HOUSE · DE	−$14K – $14K −$37K – $37K today 2 filings · last Nov 16, 2021
Greg Landsman D · HOUSE · OH	−$35K – $35K −$38K – $57K today 2 filings · last Mar 27, 2025

Recent transactions

Trades from Jun 24, 2019 – Jun 12, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Buy	71 days Jun 12, 2026 → Aug 22, 2026	≥$50K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$100K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$50K
Donald Trump R · EXECUTIVE	Sell	51 days May 11, 2026 → Jul 1, 2026	≥$50K
Jared Moskowitz D · HOUSE · FL-23	Sell	44 days May 6, 2026 → Jun 19, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	28 days Apr 13, 2026 → May 11, 2026	≥$15K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,391

13F shares

184.2M

Total invested

$52.1B

Ownership

94.7%

New positions

105

Closed positions

198

Increased positions

540

Reduced positions

630

Put/Call ratio

0.29

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	18.2M	$5.2B	−8.67%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	12.4M	$3.5B	+0.53%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	9.6M	$2.7B	+0.22%
STATE STREET CORP	9/22/2026	9.3M	$2.6B	+0.91%
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.	8/14/2026	7.4M	$2.1B	+17.74%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	7.1M	$2.0B	−2.61%
JPMORGAN CHASE & CO	8/12/2026	5.9M	$1.7B	+21.66%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	5.5M	$1.5B	−2.00%
BOSTON PARTNERS	8/4/2026	4.9M	$1.4B	+8.61%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	4.6M	$1.3B	+0.25%
FMR LLC	8/13/2026	4.1M	$1.2B	−38.35%
MORGAN STANLEY	8/13/2026	4.1M	$1.2B	−9.83%
BANK OF AMERICA CORP /DE/	8/14/2026	3.7M	$1.1B	−9.77%
NORGES BANK	8/12/2026	2.5M	$700.0M	—
GOLDMAN SACHS GROUP INC	8/14/2026	2.3M	$643.5M	+2.77%
AMUNDI	8/11/2026	2.2M	$630.9M	+43.53%
NORTHERN TRUST CORP	8/13/2026	2.2M	$610.9M	−1.09%
INVESCO LTD.	8/14/2026	2M	$572.0M	−49.31%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	2M	$560.3M	+1.04%
CARMIGNAC GESTION	8/13/2026	1.7M	$494.5M	+58.67%
MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD.	8/7/2026	1.7M	$483.8M	+25.73%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	1.7M	$483.4M	+5.68%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	1.6M	$464.2M	+5.90%
MAWER INVESTMENT MANAGEMENT LTD.	8/7/2026	1.5M	$421.3M	+44.38%
BESSEMER GROUP INC	8/12/2026	1.5M	$417.1M	+21.33%

Insider transactions

Insider	Type	Transacted	Price	Date
Sanchez Robert E	A-AWARD	275	—	Oct 1
Krikorian Lazarus	S-SALE	986	$303.18	Oct 1
Sanchez Robert E		0	—	Oct 1

Analyst consensus

Buy46 analysts

Bearish · 1 · Hold · 12 · Bullish · 33

Earnings history

	EPS	Estimate
Q4 2024	$3.34	$3.23	Beat
Q1 2025	$3.73	$3.50	Beat
Q2 2025	$4.42	$4.11	Beat
Q3 2025	$4.00	$3.85	Beat
Q4 2025	$3.84	$3.79	Beat
Q1 2026	$4.08	$4.05	Beat
Q2 2026	$4.75	$4.82	Miss
Q3 2026	$4.48	$4.35	Beat

Peers

Company overview

IPO dateApr 4, 1995

CEORobert Mauch

Employees49,000

SectorHealthcare

IndustryMedical - Distribution

CountryUS

ExchangeNew York Stock Exchange

Websitewww.cencora.com

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.